ReviewBMC cancer2025
Predictive molecular biomarkers of radiosensitivity in adult glioma: a narrative review.
Review in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most common malignant primary brain tumors in adults, yet their prognosis remains poor despite advances in treatment. Radiotherapy is a cornerstone of glioma management; however, its efficacy is often limited by tumor radioresistance. Understanding the molecular mechanisms underlying this resistance is critical for improving therapeutic outcomes. Recent research has identified key biomarkers and molecular pathways, including immune modulation, hypoxia, cell cycle regulation, apoptosis, and stress responses that influence tumor radiosensitivity and prognosis. This review explores predictive molecular biomarkers for radiosensitivity in gliomas, highlighting the latest advancements in preclinical studies and available clinical data, as well as their potential to inform future personalized radiotherapy strategies. Incorporating these biomarkers into clinical decision-making may facilitate patient stratification, guide combined modality approaches, and improve treatment precision and outcomes in glioma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.